Oral semaglutide is the peptide-delivery achievement that anchors Novo Nordisk's 2026 strategy. The molecule reaches systemic circulation through the SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) absorption enhancer, which transiently raises gastric pH at the tablet site and opens a window for the otherwise gut-degraded peptide to cross.
The US 2026 line-up: Wegovy pill, the higher-dose 25 mg formulation cleared for chronic weight management in late 2025, hit roughly 113,000 weekly retail prescriptions by early May; Ozempic pill, launched May 4 at 1.5/4/9 mg for type-2 diabetes, took the place of the retired Rybelsus US brand and uses an improved-absorption reformulation that allows smaller tablets at lower mg doses with equivalent efficacy. The PIONEER TEENS Phase 3a readout positioned oral semaglutide as the first oral GLP-1 with potential pediatric T2D approval. PIONEER PLUS established the 25 mg dose's improved A1c reduction. Novo reported Wegovy pill sales of 5.4 billion Danish kroner in the third quarter of 2026 and said the pill was on sale in eight countries. In the UK, where it was licensed in June 2026, the Advertising Standards Authority ruled on November 4 that ads from Juniper, MedExpress, and Voy had promoted it to the public.
Stories here cover the Wegovy pill, Ozempic pill, head-to-head comparisons against Foundayo, and the underlying SNAC technology. See #wegovy-pill, #ozempic-pill, and #novo-nordisk.
Medsafe has received an application for Wegovy oral tablets under one of its reliance pathways, which draw on decisions by trusted overseas regulators to halve target review times, and aims to finish the initial assessment in about 75 working days, 1News reported on November 7. No other weight-loss drug is under consideration, and the Royal New Zealand College of General Practitioners' medical director, Dr. Prabani Wood, said no decision has been made on funding and access.
Novo Nordisk reported third-quarter Wegovy pill sales of 5.4 billion Danish kroner (about $811 million), above the roughly 4.5 billion analysts expected, CNBC reported on November 4. Total sales rose 4% at constant exchange rates to 79.2 billion kroner, and Novo now expects 2026 adjusted sales and operating profit growth of -2% to +2%, up from a range of -6% to flat; the company said the pill is now sold in eight countries. CFO Karsten Munk Knudsen will leave at the end of 2026 after 27 years, to be replaced by Galderma's Luigi La Corte, and CEO Mike Doustdar said "turnaround and recovery is not done based on one data point."
The Advertising Standards Authority upheld complaints on November 4 against four ads it said promoted the oral Wegovy tablet, a prescription-only medicine licensed in the UK in June 2026: a Juniper YouTube ad ("The weight loss pill is here"), a MedExpress Instagram story ("New weight loss tablets", "No needles"), and a Voy video-on-demand ad and bus-side poster ("The weight is over") that Voy said were for a glucomannan supplement. The ASA found that pill imagery, timing soon after the launch, and click-through pages naming Wegovy or Mounjaro amounted to advertising a prescription medicine to the public, breaching CAP Code rule 12.12, and told all three companies not to do it again.
The Therapeutic Goods Administration approved Novo Nordisk's oral semaglutide tablet on Tuesday, November 3, in 1.5, 4, 9, and 25 mg strengths for adults with obesity and for lowering cardiovascular risk, ABC News reported. The TGA still has to review packaging and production before the pill can be released, no price has been set, and under current rules the Pharmaceutical Benefits Scheme subsidizes these drugs only for type 2 diabetes. Eli Lilly's orforglipron is still awaiting a TGA decision.
A 60-year-old woman developed hives, facial swelling, a closing throat, and trouble breathing within minutes of taking oral semaglutide 3 mg and needed an epinephrine injection, clinicians reported in Allergologia et Immunopathologia. An intradermal skin test was positive, pointing to an IgE allergy. Because the drug was helping her and she had no good alternative, they gave a rapid 13-step oral desensitization with premedication, and she has stayed symptom-free on daily therapy since September 2025; the authors say no standard protocol exists.
University of Pennsylvania researchers reported in JAMA Network Open on October 7, 2026 that among 47.9 million adults eligible for obesity medicines in Epic Cosmos, a database of health records from more than 2,000 U.S. hospitals, 148,792 started oral semaglutide between December 22, 2025, when the FDA approved the pill for obesity, and March 15, 2026: 87.6% on the Wegovy pill and 12.4% on Rybelsus. Weekly starts peaked at 4.56 per 10,000 eligible adults in early March, briefly exceeding starts of injectable semaglutide, and 53.0% of people starting the pill had never used a GLP-1 drug before. Compared with people starting injections, pill users were older on average, more often women (72.7%), and had a lower average BMI (36.6); the study counted prescription orders, which may not all have been filled.
Novo presented at EASD on Wednesday, September 30, 2026 OCTANE, a retrospective analysis of de-identified data from the telehealth company Ro covering 194 adults who switched from injectable semaglutide or tirzepatide to the once-daily Wegovy pill between January 5 and February 7, 2026. From a mean baseline weight of 100.5 kg and BMI of 34.5, participants lost an average of 4.1% of body weight (4.0 kg) over three months, 40.7% lost at least 5%, and the share with a BMI of 30 or higher fell from 87.1% to 65.5%. Novo listed limitations including self-reported and incomplete data and selection bias from counting only people who stayed on treatment; the release did not give the injectable doses people switched from.
Lilly announced on Tuesday, September 29, 2026 an indirect treatment comparison, presented at EASD, of its oral small-molecule GLP-1 drug Foundayo (orforglipron) 17.2 mg against Novo's oral semaglutide 25 mg in adults with type 2 diabetes, using data from Lilly's ACHIEVE-3 trial and Novo's PIONEER PLUS trial. At 52 weeks, Foundayo was associated with 1.5 percentage points more weight loss (95% CI -2.7 to -0.2) and a 0.3-point larger A1C reduction (95% CI -0.6 to -0.1); sensitivity analyses gave 1.5 to 2.4 points and 0.3 to 0.6 points. Lilly's Rachel Batterham said head-to-head trials give the best comparison of two medicines, and the two drugs have not been tested directly against each other at these doses.
Novo Nordisk (NYSE: NVO) commercially launched Wegovy pill (oral semaglutide 25 mg for chronic weight management) in Germany on Tuesday September 1, 2026, the first European market for the once-daily oral obesity formulation after the U.S. launch in January 2026. Wegovy pill was FDA-approved in December 2025 as the first oral GLP-1 receptor agonist for obesity, and has topped 5 million cumulative U.S. prescriptions in the first 8 months per Novo Nordisk H1 2026 disclosures. The German launch positions Wegovy pill against Eli Lilly's Foundayo (orforglipron, small-molecule oral GLP-1) which received FDA approval April 1, 2026 and is preparing for European launch pending EMA review. The oral formulation is intended to address patient-preference research showing that 71% of adults with obesity prefer a daily pill over a weekly injection when taking prescription weight-loss medication. Under the German AMNOG process, national reimbursement negotiation will follow marketing launch over the next 6-12 months.
Novo Nordisk (NYSE: NVO) shares fell approximately 5% across Tuesday and Wednesday August 4-5, 2026 following the H1 2026 earnings release. CEO Lars Fruergaard Jorgensen defended Wegovy pill economics on the earnings call, addressing analyst concerns about the compressed margin trajectory from the Most-Favored-Nation pricing deals announced with the Trump administration in November 2025 (which paired lower drug prices with expanded Medicare access and a three-year tariff grace period) and the Medicare GLP-1 Bridge Program launched July 1, 2026 (providing Wegovy, Zepbound KwikPen, and Foundayo at a capped $50/month copay for eligible Medicare Part D beneficiaries through December 31, 2027). Both programs reduce net realized prices per unit even as prescription volume climbs. Wegovy pill (oral semaglutide 25 mg for obesity) has reached more than 5 million cumulative US prescriptions since the Q1 2026 launch, one of the fastest oral obesity-drug uptake curves on record. Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency); the company raised full-year 2026 guidance from prior expectations to down 6% to flat at constant exchange rates. Analyst attention now focuses on 2027 pricing environment and Novo's ability to defend franchise economics as Eli Lilly's tirzepatide and orforglipron continue to widen the competitive gap.
Novo Nordisk reported Q2 2026 earnings Tuesday August 4, 2026 with sales of 78.49 billion Danish kroner ($12.09 billion, +3% constant currency, +7% adjusted). Franchise performance: Wegovy injectable reached 19.484 billion DKK (+1% year-over-year); Wegovy pill (oral semaglutide 25 mg for obesity, launched Q1 2026) generated 3.218 billion DKK on more than 5 million cumulative prescriptions since launch; Ozempic (semaglutide for type 2 diabetes) grew 3% to 31.375 billion DKK. Novo Nordisk hiked its 2026 adjusted sales guidance to down 6% to flat at constant exchange rates, an improvement from the previous guidance that had reflected the substantially compressed pricing environment from the Trump administration Most-Favored-Nation deals and the July 1 Medicare GLP-1 Bridge Program launch. The Wegovy pill launch trajectory (5 million prescriptions in roughly six months) is one of the fastest oral obesity-drug uptake curves on record and effectively confirms the strength of the SNAC-enhanced oral peptide formulation strategy that Novo has pursued since the 2019 Rybelsus approval for type 2 diabetes. Novo shares tanked despite the raised outlook, reflecting concern about the tough Q2 2025 comparison and margin trajectory into 2027.
Fierce Pharma's weekly Oral GLP-1 Tracker, which leverages IQVIA data and analyst notes, reports that Eli Lilly's Foundayo (orforglipron) reached 19,879 US prescriptions in its ninth week of retail launch compared with 159,000 for Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) in its 22nd week. Foundayo received FDA approval April 1, 2026 and began retail shipments through LillyDirect on April 6; the Wegovy pill received FDA approval December 22, 2025 and launched in early January 2026. Adjusting for launch timing, Foundayo tracks numerically behind Wegovy pill at equivalent weeks, though Lilly executives noted on the Q1 earnings call that Foundayo's first-week pace ran ahead of the Zepbound injectable launch (2024). Spherix Global Insights analysis attributes Wegovy pill's uptake advantage to first-mover positioning and physician familiarity with the Wegovy brand name established through the injectable franchise. Foundayo's Q2 sell-in run rate implies roughly $146 million in Q2 revenue and $1.6 billion for full-year 2026 by analyst modeling.
Novo Nordisk announced on June 11 that the UK Medicines and Healthcare products Regulatory Agency had approved the Wegovy pill (oral semaglutide tablets 25 mg) for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, making the UK the third national authority to license the molecule after the FDA and the UAE's EDE. The approval rests on the Phase 3 OASIS 4 trial, which showed about 13.6% weight loss with the 25 mg tablet versus 2% on placebo. Private-prescription availability is expected within weeks; NHS coverage requires a separate NICE cost-effectiveness appraisal.
Novo Nordisk launched the Wegovy pill in the United Arab Emirates on June 3, the first country outside the US to make the oral semaglutide tablet available since the January 5 US launch. The UAE rollout used a distribution structure that piggybacks on existing diabetes-channel infrastructure rather than a parallel direct-to-consumer build, and arrived ahead of the UK MHRA approval today. Novo had previously guided to second-half 2026 for international rollouts.
A June 7 Novo Nordisk announcement, timed to ADA 2026, said the Wegovy pill (oral semaglutide 25 mg) had surpassed 3 million US prescriptions since its January 5 launch, with one prescription filled roughly every five seconds. The first million took 12 weeks (to March 23); the next 2 million came in 10 weeks. More than 80% of new Wegovy pill scripts go to patients new to GLP-1 therapy, suggesting market expansion rather than brand switching, and the first international launches outside the US are set for the second half of 2026.
Novo Nordisk announced on May 22 that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency adopted a positive opinion recommending marketing authorization of Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain long-term weight reduction. The recommendation includes data from SELECT in the label — the cardiovascular outcomes trial that documented a 20% major adverse cardiovascular event reduction with injectable Wegovy. The CHMP opinion is the first oral GLP-1 EU approval recommendation for weight management. OASIS 4 Phase 3 data anchoring the filing: 16.6% mean weight loss in adults with obesity or overweight plus one comorbidity, comparable to injectable Wegovy 2.4 mg. Novo plans to launch the pill in select non-US markets in H2 2026, with UK, Germany, and Denmark previously flagged as the first international launches (CNBC May 18). The CHMP opinion confirms the international expansion path Novo's EVP Larsen described.
Novo Nordisk's Executive Vice President for International Operations Emil Kongshøj Larsen told CNBC May 18 the company is preparing to go 'all in' on launching its Wegovy pill outside the US, with UK, Germany, and Denmark at the front of the international queue. The company disclosed cumulative US Wegovy pill prescriptions have crossed 2 million in the 18 weeks since the January 5 launch — roughly double the >1M figure CEO Maziar Doustdar shared on May 14. Larsen's quote: 'When we launch, we'll go all in.' The international expansion lands as Novo's full-year 2026 guidance still calls for revenue and profit declines between 4% and 12%, but the company hiked guidance slightly last week after Q1 oral semaglutide sales beat expectations. The international Wegovy pill timing matters for Lilly's Foundayo (orforglipron), which had its US PBM coverage activate mid-May but has no near-term international launch date.
The CNBC May 18 piece surfaced explicit company-supported positioning that Foundayo (orforglipron) and oral Wegovy are targeting different patient segments rather than competing head-to-head. Novo's framing for Wegovy pill is 'injectable-like efficacy' in oral form, with the Phase 3 OASIS-MAINTAIN data anchoring approximately 15% mean weight loss. Lilly's framing for Foundayo positions it as more of a 'starter' GLP-1 — lower weight-loss ceiling (around 11.2% in ATTAIN-1) but no food-or-water dosing restrictions and a non-peptide small-molecule manufacturing path that supports a lower long-term price. Both companies say the pills are expanding the market rather than significantly cannibalizing demand for the injectables — a different framing than the 'oral-disrupts-injectable' narrative that dominated 2025 coverage. The market-expansion hypothesis will be testable as ADA 2026 (June 5-8) and Q2 2026 earnings prints land.